Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Interaction of Mantle Cell Lymphoma with the Microenvironment Induces Phospho Akt-Mediated Resistance Against BTK Inhibition and Can be Overcome By Co-Treatment with a Specific Akt Inhibitor (MK-2206)

Elisabeth Silkenstedt, MD, Claudia Schwandner, Johanna Deuss, Natalie Mack, Yvonne Zimmermann, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 2802.

https://doi.org/10.1182/blood-2019-128782

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas

Przemyslaw Kiliszek, MSc, Maciej Szydlowski, PhD, Tomasz Sewastianik, MSc, Ewa Jablonska, PhD, Emilia Bialopiotrowicz, PhD, Patryk Gorniak, PhD, Anna Polak, MSc, Sergiusz Markowicz, PhD, Eliza Nowak, MSc, Monika A. Grygorowicz, MSc, Monika Prochorec-Sobieszek, MD PhD, Anna Szumera-Cieckiewicz, MD PhD, Agata Malenda, MD PhD, Ewa Lech-Maranda, MD PhD, Krzysztof Warzocha, MD PhD, Przemyslaw Juszczynski, MD PhD

Blood (2015) 126 (23): 314.

https://doi.org/10.1182/blood.V126.23.314.314

Published: 2015

Journal Articles

Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Sarah Meadows, Sorensen Rick, Yahiaoui Anella, Jia Liu, PhD, Li Li, PhD, Peng Yue, PhD, Christophe Queva, PhD, Stacey Tannheimer, PhD

Blood (2015) 126 (23): 3707.

https://doi.org/10.1182/blood.V126.23.3707.3707

Published: 2015

Journal Articles

Inhibition of Akt Signaling Alleviates MDS/MPN Driven By Kras D12 or Nf1 Loss

Tannie Huang, MD, Jon Akutagawa, Inbal Epstein, Charisa Cottonham, PhD, Maricel Quirindongo-Crespo, Benjamin S. Braun, MD PhD

Blood (2015) 126 (23): 360.

https://doi.org/10.1182/blood.V126.23.360.360

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma

Yasuhiro Oki, MD, Michelle A. Fanale, MD, Jorge E. Romaguera, MD, Luis Fayad, MD, Nathan Fowler, MD, Amanda R. M. Copeland, MSN, Felipe Samaniego, MD, Larry W. Kwak, MD PhD, Sattva S Neelapu, MD, Michael Wang, MD, Lei Feng, MS, Anas Younes

Blood (2014) 124 (21): 3093.

https://doi.org/10.1182/blood.V124.21.3093.3093

Published: 2014

Journal Articles

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Leopold Sellner, MD, Malgorzata Oles, Tea Pemovska, MSc, Paavo Pietarinen, MSc, Anneli Lauhio, MD, Katarzyna Tomska, Carlos Cuesta-Mateos, MD PhD, Edgar Faber, Tim H. Brummendorf, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD, Wolfgang Huber, PhD, Krister Wennerberg, PhD, Thorsten Zenz, MD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 917.

https://doi.org/10.1182/blood.V124.21.917.917

Published: 2014

Journal Articles

Novel Phenotypic and Genetic Analysis of T-Cell Prolymphocytic Leukemia (T-PLL)

Henan Zhang, Esteban Braggio, PhD, Jaime Davila, PhD, Andrew L. Feldman, MD, Timothy G. Call, MD, Thomas E. Witzig, MD, Yi Lin, MDPhD, Charla Secreto, Mrinal M. Patnaik, MBBS, James R Cerhan, MD PhD, Sameer A. Parikh, MD, Saurabh Baheti, Wei Ding, MD PhD

Blood (2014) 124 (21): 1682.

https://doi.org/10.1182/blood.V124.21.1682.1682

Published: 2014

Journal Articles

Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors

Christopher A. Eide, Samantha L. Savage, Jade Bryant, Anupriya Agarwal, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Thomas O'Hare, Michael W. Deininger, Marc M. Loriaux, Cristina E. Tognon, Jeffrey W. Tyner, Brian J. Druker

Blood (2013) 122 (21): 3994.

https://doi.org/10.1182/blood.V122.21.3994.3994

Published: 2013

Journal Articles

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Andrew Skomra, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan Lim, MD, PhD, Aradhana Awasthi, Ph.D, Mitchell S. Cairo, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2013) 122 (21): 5144.

https://doi.org/10.1182/blood.V122.21.5144.5144

Published: 2013

Journal Articles

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Emma I Andersson, MSc, Tea Pemovska, MSc, Samuli Eldfors, MSc, Anneli Lauhio, MD, Paavo Pietarinen, MSc, Edgar Faber, MD, PhD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline Heckman, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 3828.

https://doi.org/10.1182/blood.V122.21.3828.3828

Published: 2013

Journal Articles

Dose-Response Titration In a Bone Marrow Niche Model Reveals AKT As a Target That Modulates Sensitivity Of Myeloid Leukemia To Extracellular Matrix Mechanics: Implications In Drug Resistance

Jae-Won Shin, Ph.D., David J. Mooney, Ph.D.

Blood (2013) 122 (21): 1292.

https://doi.org/10.1182/blood.V122.21.1292.1292

Published: 2013

Journal Articles

Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter

Beata Pyrzynska, PhD, Kamil Bojarczuk, MSc, Magdalena Winiarska, PhD, Jacek Bil, MD, PhD, Nina Miazek, Piotr Zapala, Malgorzata Bobrowicz, MSc, Michal Dwojak, Marta Siernicka, Jakub Golab, M.D., Ph.D.

Blood (2013) 122 (21): 1838.

https://doi.org/10.1182/blood.V122.21.1838.1838

Published: 2013

Journal Articles

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Atsushi Nonami, MD, PhD, Martin Sattler, PhD, Ellen L. Weisberg, PhD, Jianming Zhang, PhD, Qingsong Liu, PhD, Matthew Patricell, PhD, Hojong Yoon, Amanda L. Christie, B.S., Amy M. Sauer, Nancy Kohl, PhD, Andrew L. Kung, MD, PhD, Taebo Sim, PhD, Nathanael S. Gray, PhD, James D. Griffin, MD

Blood (2013) 122 (21): 169.

https://doi.org/10.1182/blood.V122.21.169.169

Published: 2013

Journal Articles

The Small Gtpase Rap1b Negatively Regulates Neutrophil Migration During Inflammation By Limiting Trans-Cellular Diapedesis

Sachin Kumar, PhD, Juying Xu, Magdalena Chrzanowska-Wodnicka, Ph.D., Marie-Dominique Filippi, PhD

Blood (2013) 122 (21): 320.

https://doi.org/10.1182/blood.V122.21.320.320

Published: 2013

Journal Articles

Dual Inhibition Of PI3K and mTOR Shows Preferential Antileukemic Activity In MLL -Rearranged AML

Nadine Sandhöfer, Klaus H. Metzeler, MD, Tanja Hinrichsen, Sebastian Tiedt, Evelyn Zellmeier, Volker Groiß, Oliver Wachter, Hanns-Georg Klein, MD, Wolfgang Hiddemann, MD, Irmela Jeremias, MD, Karsten Spiekermann, MD

Blood (2013) 122 (21): 818.

https://doi.org/10.1182/blood.V122.21.818.818

Published: 2013

Journal Articles

Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor

Ravi Dashnamoorthy, Ph.D., Savita Bhalla, PhD, Jennifer Crombie, Irawati Kandela, Ph.D., Andrew Mazar, Ph.D., Andrew M. Evens, DO, MSc

Blood (2012) 120 (21): 1646.

https://doi.org/10.1182/blood.V120.21.1646.1646

Published: 2012

Journal Articles

Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy

Connie Lesnick, M.Sc, Asish K Ghosh, PhD, Betsy R. LaPlant, Wei Ding, MD, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2012) 120 (21): 3927.

https://doi.org/10.1182/blood.V120.21.3927.3927

Published: 2012

Journal Articles

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Daniela Buglio, MD, PhD, Manuela Lemoine, PhD, Jaymie Estrella, PhD, Sattva S. Neelapu, MD, Richard Eric Davis, MD, Laurence Doyle, MD, Richard F Little, MD, MPH, Donald Berry, Anas Younes, MD

Blood (2011) 118 (21): 3729.

https://doi.org/10.1182/blood.V118.21.3729.3729

Published: 2011

NARROW

Interaction of Mantle Cell Lymphoma with the Microenvironment Induces Phospho Akt-Mediated Resistance Against BTK Inhibition and Can be Overcome By Co-Treatment with a Specific Akt Inhibitor (MK-2206)

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas

Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Inhibition of Akt Signaling Alleviates MDS/MPN Driven By Kras D12 or Nf1 Loss

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Novel Phenotypic and Genetic Analysis of T-Cell Prolymphocytic Leukemia (T-PLL)

Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Dose-Response Titration In a Bone Marrow Niche Model Reveals AKT As a Target That Modulates Sensitivity Of Myeloid Leukemia To Extracellular Matrix Mechanics: Implications In Drug Resistance

Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

The Small Gtpase Rap1b Negatively Regulates Neutrophil Migration During Inflammation By Limiting Trans-Cellular Diapedesis

Dual Inhibition Of PI3K and mTOR Shows Preferential Antileukemic Activity In MLL -Rearranged AML

Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor

Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only